Diagnosis and Management of Rheumatoid Arthritis
TUESDAY, March 19, 2019
12:15pm—Hope Conference Center
DIAGNOSIS AND MANAGEMENT OF RHEUMATOID ARTHRITIS
PENG FAN, MD
CLINICAL PROFESSOR OF MEDICINE, DIVISION OF RHEUMATOLOGY
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
PLANNER/MODERATOR:
Nilesh Desai, MD, Department of Medicine liaison to the Medical Education Committee, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Desai states he has no financial arrangements with any commercial company to disclose. Dr. Fan discloses he is on the Speakers Bureau for Amgen, Novartis, Pfizer, Sanofi, Genzyme, Abbrie, Radius, Regeneron. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 5-15-19
Review Date: 5/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
3/19/2019
|
|
Peng
Fan
|
|
Presenter
|
|
Hope Conference Center
|
|
|
Complete Video Confirmation
In order to complete the evaluation, you must log in.
|
|
The Path to Personalized Medicine in IBD
|
|
TUESDAY, April 9, 2019
12:15pm--Hope Conference Center
THE PATH TO PERSONALIZED MEDICINE IN IBD
DERMOT P.B. MCGOVERN, MD, PHD, MRCP
DIRECTOR, TRANSLATIONAL MEDICINE
F. WIDJAJA FOUNDATION INFLAMMATORY BOWEL AND IMMUNOBIOLOGY RESEARCH
INSTITUTE, CEDARS-SINAI MEDICAL CENTER
PLANNER/MODERATOR:
Ora Gordon, MD, MS; Regional Medical Director, Center for Clinical Genetics & Genomics; Medical Director, Integrative Medicine, Roy and Patricia Disney Family Cancer Center, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Gordon states she has no financial arrangements with any commercial company to disclose. Dr. McGovern discloses he is a consultant for Precision IBD, Gilead, Janssen, Bridge Therapeutics, Qu Biologics, and Pfizer, and has received grant support from Janssen and Second Genome. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 5-15-19
Review Date: 5/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
|
|
Recognition and Management of Osteoarthritis
|
|
THURSDAY, March 14, 2019
12:15pm, Hope Conference Center
RECOGNITION AND MANAGEMENT OF OSTEOARTHRITIS
PENG FAN, MD
CLINICAL PROFESSOR OF MEDICINE, DIVISION OF RHEUMATOLOGY
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
PLANNER/MODERATOR:
Nilesh Desai, MD, Department of Medicine liaison to the Medical Education Committee, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Desai states he has no financial relationship with a commercial company to disclose. Dr. Fan discloses he is on the Speakers Bureau for Amgen, Novartis, Pfizer, Sanofi, Genzyme, Abbrie, Radius, Regeneron. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
This activity satisfies DHS radiology requirements for renewal of fluoroscopy permit.
Release Date: 5-15-19
Review Date: 5/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
Heart Failure: When to Consider Bridge Devices or Transplantation
|
|
TUESDAY, February 26, 2019
HEART FAILURE: WHEN TO CONSIDER BRIDGE DEVICES OR TRANSPLANTATION
JON KOBASHIGAWA, MD
DSL/THOMAS D. GORDON CHAIR IN HEART TRANSPLANTATION MEDICINE
CEDARS-SINAI MEDICAL CENTER
PLANNER/MODERATOR:
Daniel Eisenberg, MD, Medical Director, Cardiac Services, PSJMC
FACULTY/PLANNER DISCLOSURES:
It is our policy to ensure that planners, faculty and content are independent of commercial bias. Dr. Eisenberg states he has no financial arrangements with any commercial company to disclose. Dr. Kobashigawa states he has received consulting fees from CareDX and research grants from CareDX, Novartis, and Sanofi/Genzyme. It is our policy to review presentations ahead of time in order to resolve any potential conflicts of interest. No conflicts were identified in the review of today’s presentation.
Disclosures for members of the Medical Education Committee may be found at the CME sign-in desk and on the CME website at
www.providencecme.org.
Click Here For Learning Objectives
Release Date: 4-12-19
Review Date: 4/22
Termination Date:
This activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
|